The next $4 million in donations to MAPS will be matched dollar-for-dollar by the Pineapple Fund until March 10, 2018. If this funding challenge is met in gifts, grants, and multi-year pledges, MAPS will have raised sufficient funds to complete our Phase 3 trials of MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder (PTSD). Donate to support Phase 3 trials by March 10th and your donation will be doubled!!
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to MDMA-assisted psychotherapy in August 2017, acknowledging that it "may demonstrate substantial improvement over existing therapies." If MAPS receives the necessary funding and the trials show positive results, FDA approval is expected by 2021. MAPS estimates that Phase 3 clinical trials will cost $26 million. With $17.3 million already raised or pledged, MAPS still needs $8.7 million to make MDMA-assisted psychotherapy legally available to millions of people suffering with PTSD.
This is your opportunity to make DOUBLE THE IMPACT on proving life-changing treatment for people suffering from trauma that impacts not only their own life, but everyone around them. The time is now to change the future of humanity!
Learn more at http://www.maps.org/research/mdma/ptsd/phase3